Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr;197(4):225-31.
doi: 10.1097/NMD.0b013e31819db6fe.

Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up

Suzette Glasner-Edwards  1 , Patricia Marinelli-Casey, Maureen Hillhouse, Alfonso Ang, Larissa J Mooney, Richard Rawson; Methamphetamine Treatment Project Corporate Authors
Collaborators, Affiliations
Randomized Controlled Trial

Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up

Suzette Glasner-Edwards et al. J Nerv Ment Dis. 2009 Apr.

Abstract

Although depression is highly comorbid with substance use disorders, little is known about the clinical course and outcomes of methamphetamine (MA) users with depressive symptoms and syndromes. In this study of MA-dependent individuals entering psychosocial treatment, we predicted that (1) depressive symptoms would decline during treatment, an effect that would vary as a function of MA use and (2) depression diagnoses post-treatment would be associated with poorer outcomes. Participants (N = 526) were assessed for depression, substance use, and psychosocial outcomes at baseline, treatment discharge, and 3-year follow-up. Depressive symptoms declined significantly during treatment, an effect that was greatest among those who abstained from MA. Major depression at follow-up was associated with poorer MA use outcomes and impairment across multiple domains of functioning. The findings highlight the relationship of depressive symptoms and diagnoses to treatment outcomes, and suggest a need for further studies of depression in populations using MA.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Mean total BDI score as a function of time, separated by self-reported MA use status during the 30 days before treatment discharge (Abstinent = no MA use; Used MA = 1 or more days of MA use during the 30 days before discharge).
FIGURE 2
FIGURE 2
Mean ASI composite scores as a function of time among MA dependent adults with (N = 80; upper panel) and without (N = 446; lower panel) MDD at 3-year follow-up.
FIGURE 3
FIGURE 3
Mean BSI scale scores as a function of time among MA dependent adults with (N = 80; upper panel) and without (N = 446; lower panel) MDD at 3-year follow-up.
See this image and copyright information in PMC

References

    1. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck depression inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77–100.
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. - PubMed
    1. Brown RA, Monti PM, Myers MG, Martin RA, Rivinus T, Dubreuil ME, Rohsenow DJ. Depression among cocaine abusers in treatment: Relation to cocaine and alcohol use and treatment outcome. Am J Psychiatry. 1998;155:220–225. - PubMed
    1. Cannon DS, Rubin A, Keefe CK, Black JL, Leeka JK, Phillips LA. Affective correlates of alcohol and cocaine use. Addict Behav. 1992;17:517–524. - PubMed
    1. Carroll KM, Nich C, Rounsaville BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J Nerv Ment Dis. 1995;183:251–259. - PubMed

Publication types

Substances